Nymox is a pre-revenue biopharmaceutical company focused on developing its sole drug candidate, fexapotide triflutate (NX-1207). NX-1207 is an injectable treatment designed for benign prostatic hyperplasia, an enlarged prostate condition that affects urinary function in older men. Nymox is also evaluating NX-1207 as a potential treatment for low-grade localized prostate cancer and, in preclinical studies, hepatocellular carcinoma. The company has no approved products on the market, generates no product revenue, and maintains no commercial sales force. NX-1207 has not received regulatory approval in any jurisdiction, though a marketing authorization application remains under review in the United Kingdom. Nymox's business model depends entirely on obtaining regulatory approvals for NX-1207 and commercializing the drug, either directly or through licensing, co-promotion, or co-marketing partnerships with established pharmaceutical companies. Nymox finances its ongoing research, clinical development, and operational activities through equity issuances.